BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED Beijing Tong Ren Tang Chinese Medicine Company Limited Share Price Deutsche Boerse AG
Equities
TQR
HK0000145638
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.19 EUR | -0.83% |
|
0.00% | -14.39% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.74B 222M 205M 18.52B | Sales 2025 * | 1.99B 255M 235M 21.22B | Capitalization | 8.62B 1.11B 1.02B 92.01B |
|---|---|---|---|---|---|
| Net income 2024 * | 652M 83.57M 76.91M 6.96B | Net income 2025 * | 758M 97.15M 89.41M 8.09B | EV / Sales 2024 * | 3.34 x |
| Net cash position 2024 * | 2.83B 363M 334M 30.23B | Net cash position 2025 * | 2.63B 337M 311M 28.09B | EV / Sales 2025 * | 3.01 x |
| P/E ratio 2024 * |
13.3
x | P/E ratio 2025 * |
10.3
x | Employees | 798 |
| Yield 2024 * |
3.88% | Yield 2025 * |
4.51% | Free-Float | 28.23% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.83% | ||
| Current month | +3.48% | ||
| 1 month | +11.21% | ||
| 3 months | +5.31% | ||
| 6 months | -15.00% | ||
| Current year | -14.39% |
1 week
1.19
1.23
1 month
1.071.23
Current year
1.031.45
1 year
1.031.87
3 years
1.031.89
5 years
0.831.89
10 years
0.831.89
| Managers | Title | Age | Since |
|---|---|---|---|
Fung Yi Tsang
DFI | Director of Finance/CFO | 48 | 01/12/01 |
Xia Li
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/08/01 |
Fei Chen
BRD | Director/Board Member | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ngai Chi Chan
BRD | Director/Board Member | 52 | 15/13/15 |
Hai Ou Gu
CHM | Chairman | 58 | 13/12 |
Yok Sing Tsang
BRD | Director/Board Member | 76 | 12/17/12 |
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.19 | -0.83% |
| 16/24/16 | 1.2 | -1.64% |
| 15/24/15 | 1.22 | -0.81% |
| 14/24/14 | 1.23 | +1.65% |
| 13/24/13 | 1.21 | +1.68% |
Delayed Quote Deutsche Boerse AG, May 17, 2024 at 11:33 am IST
More quotes
Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. It is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.3
HKD
Average target price
13.92
HKD
Spread / Average Target
+35.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 3613 Stock
- TQR Stock